Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
total body irradiation + cyclophosphamide
- Development stage
- Unknown
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
- Administration
- External Radiation, Intravenous
01
Overview
TBICy is a myeloablative conditioning regimen used prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT), primarily for patients with acute lymphoblastic leukemia (ALL). It consists of total body irradiation (TBI) and high-dose cyclophosphamide. TBI serves as a potent anti-leukemic and immunosuppressive agent, capable of reaching sanctuary sites like the central nervous system and testes, while cyclophosphamide acts as a DNA alkylating agent to further eradicate malignant cells. The regimen is often compared to chemotherapy-only conditioning, such as busulfan plus cyclophosphamide (BuCy), to balance efficacy against toxicities like interstitial pneumonitis, cataracts, and secondary malignancies.
- Other names
- TBI-CyTBICyTBI/Cytotal body irradiation and cyclophosphamide
02
Targets
DNA
Beyond the preview
Go deeper on total body irradiation + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on total body irradiation + cyclophosphamide.